Patient demographic data, affected sinuses and veins, and reduction of lesion volume at follow-up

Patient No./Age (y)/SexLocation of ThrombosisRecanalization on First Follow-upFollow-up Time (mo)Parenchymal DamageHemorrhageReduction of Lesion Volume (%) Compared to Initial Study
T1-WeightedT2-Weighted
O1O2O3O1O2O3
1/27/FCortical veins9ParietalNo100100100100100100
2/44/FSSS, TSNo6FrontoparietalYes8210029100
3/43/FSTNo9Occipital, cerebellarYes10010010093100100
4/29/FSSSNo9FrontalNo100100
5/18/FSSS, STNo9OccipitalNo100100100100
6/56/FSSS, STNo6CerebellarYes68968994
7/26/FCortical veins8ParietalNo100100100100
8/35/FSSS, STNo10FrontoparietalNo43901002359100
9/33/FSSS, ST, SSYes<1Frontal, occipitalNo100100
10/39/FICV, SRYes4ThalamusNo100100
11/30/FSTYes11Occipital, cerebellarNo100100100100100100
12/37/FSSS, STNo16TemporalYes45803062
13/66/MSSS, ST, SSNo18Parietal, occipitalYes63607374
14/78/FICVYes23Basal gangliaNo5010010064100100
15/29/FSTYes10CerebellarNo54725472
  • Note.—SSS indicates superior sagittal sinus; TS, transverse sinus; SS, sigmoid sinus; ICV, inner cerebral veins; SR, straight sinus; O1–3, observation periods after initial MR imaging (O1, days 1–30; O2, days 90–240; O3, >240 days).